Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Ann Dermatol Venereol ; 148(2): 94-100, 2021 Jun.
Article in English | MEDLINE | ID: mdl-33551211

ABSTRACT

BACKGROUND: A marked increase in frequency of acute acral eruptions (AAE) was observed in children during the COVID-19 pandemic in the spring period. OBJECTIVES: In this observational multicenter study, based on children with AAE, we aimed to assess the proportion of household members possibly infected by SARS-CoV-2. METHODS: We collected data from all children observed with AAE, prospectively from April 7, 2020 to June 22, 2020, and retrospectively since February 28, 2020. The primary outcome was the household infection rate, defined as the proportion of family clusters having at least one member with COVID-19 infection other than the child with AAE ("index child"). The definition of a case was based on characteristic clinical signs and a positive PCR or serology. RESULTS: The study included 103 children in 10 French departments and in Quebec. The median age was 13 years and the interquartile range [8-15], with a female-to-male ratio of 1/1.15. In children with AAE, all PCR tests were negative (n=18), and serology was positive in 2/14 (14.3%) cases. We found no significant anomalies in the lab results. A total of 66 of the 103 families (64.1%) of included children had at least one other infected member apart from the index child. The total number of household members was 292, of whom 119 (40.8%) were considered possibly infected by SARS-CoV-2. No index children or households exhibited severe COVID-19. DISCUSSION: Among the 103 households included, 64.1% had at least one infected member. Neither children with AAE nor their households showed severe COVID-19.


Subject(s)
COVID-19/complications , Family , Adolescent , Antibodies, Antinuclear/blood , COVID-19/transmission , Chilblains/pathology , Child , Erythema/pathology , Female , Hidradenitis/pathology , Humans , Immunoglobulin G/blood , Lymphocytes/pathology , Male , Mucinoses/pathology , Pandemics , Retrospective Studies , Skin/pathology , Vasculitis/pathology
2.
Br J Dermatol ; 169(6): 1265-71, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24032480

ABSTRACT

BACKGROUND: Linear morphoea (LM) is a rare fibrosing disorder of the limbs or the face that may cause functional disability and severe aesthetic sequelae. Despite a wide range of therapeutics reported for LM, there is currently a lack of consensus on the optimal therapy. Little is known about the long-term outcome of this disease. OBJECTIVES: To describe the short- and long-term outcome of a large series of patients with LM acquired in childhood. METHODS: A retrospective chart review of 52 paediatric patients with LM seen in our centre during a 20-year span (1990-2010) and a telephone survey in 2011 to assess the long-term outcome of these patients. RESULTS: Limbs were affected twice as often as the face, with a higher proportion of female patients. Stabilization was obtained after a mean disease duration of 5·4 years. Patients sometimes experienced long stretches of disease quiescence followed by reactivation; 31% of patients reported active disease after 10 years. All but one patient had aesthetic sequelae, and 38% had functional limitations. The effectiveness of methotrexate and systemic corticosteroids was apparent in the short term. CONCLUSIONS: LM needs prolonged monitoring as the disease can have very long periods of quiescence followed by reactivation. The combination of methotrexate and systemic corticosteroids was effective in the early stages of the disease but did not seem to prevent long-standing active disease or relapse in the long term.


Subject(s)
Dermatologic Agents/therapeutic use , Scleroderma, Localized/therapy , Adolescent , Adrenal Cortex Hormones/therapeutic use , Age of Onset , Aminoquinolines/therapeutic use , Calcitriol/analogs & derivatives , Calcitriol/therapeutic use , Child , Drug Therapy, Combination , Female , Humans , Imiquimod , Male , Methotrexate/therapeutic use , Ointments , Phototherapy/methods , Retrospective Studies , Scleroderma, Localized/pathology , Tacrolimus/therapeutic use , Treatment Outcome , Vitamin A/therapeutic use , Vitamin E/therapeutic use
4.
Eur J Hum Genet ; 8(5): 372-80, 2000 May.
Article in English | MEDLINE | ID: mdl-10854098

ABSTRACT

HED is an autosomal dominant skin disorder that is particularly common in the French Canadian population of south-west Quebec. We previously mapped the HED gene to the pericentromeric region of chromosome 13q using linkage analysis in eight French Canadian families. In this study, we extend our genetic analysis to include a multiethnic group of 29 families with 10 polymorphic markers spanning 5.1 cM in the candidate region. Two-point linkage analysis strongly suggests absence of genetic heterogeneity in HED in four families of French, Spanish, African and Malaysian origins. Multipoint linkage analysis in all 29 families generated a peak lod score of 53.5 at D13S1835 with a 1 lod unit support interval spanning 1.8 cM. Recombination mapping placed the HED gene in a 2.4 cM region flanked by D13S1828 proximally and D13S1830 distally. We next show evidence for a strong founder effect in families of French Canadian origin thereby representing the first example of a founder disease in the south-west part of the province of Quebec. Significant association was found between HED in these families and all markers analysed (Fisher's exact test, P < 0.001). Complete allelic association was detected at D13S1828, D13S1827, D13S1835, D13S141 and D13S175 (P(excess) = 1) spanning 1.3 cM. A major haplotype including all 10 associated alleles was present on 65% of affected chromosomes. This haplotype most likely represents the founder haplotype that introduced the HED mutation into the French Canadian population. Luria-Delbrück equations and multipoint likelihood linkage disequilibrium analysis positioned the gene at the D13S1828 locus (likely range estimate: 1.75 cM) and 0.58 cM telomeric to this marker (support interval: 3.27 cM) respectively.


Subject(s)
Chromosomes, Human, Pair 13 , Ectodermal Dysplasia/genetics , Founder Effect , Alleles , Canada/ethnology , Chromosome Mapping , Female , Genotype , Haplotypes , Humans , Linkage Disequilibrium/genetics , Male , Pedigree
5.
Radiology ; 212(3): 841-5, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10478255

ABSTRACT

PURPOSE: To describe the diagnostic features, appearance, and vascularization pattern of venous malformations (VMs) at Doppler ultrasonography (US). MATERIALS AND METHODS: Between February 1991 and May 1997, 51 soft-tissue VMs were studied with Doppler US in patients between 1 day and 21 years of age (mean age, 9 years). These VMs were located in the maxillofacial region (n = 19), trunk (n = 5), and upper (n = 10) and lower (n = 17) extremities. Twenty-three VMs had venographic confirmation, seven had only histologic confirmation, and 21 had both venographic and histologic confirmation. US was performed with 7.5- or 7-10-MHz linear transducers, a low pulse repetition frequency (mean, 1,680 Hz), and the lowest wall filter (25-50 Hz). RESULTS: At gray-scale US, VMs appeared as hypoechoic, heterogeneous lesions in 82% of cases. All lesions displayed compressibility. In eight lesions (16%), phleboliths were identified, thus confirming the diagnosis of VM. Analysis of vascular flow revealed monophasic, low-velocity flow in 40 VMs (78%), with an average flow velocity of 0.22 kHz. Biphasic flow was noted at the periphery of three lesions, which is indicative of a mixed capillary-venous malformation. The remaining eight lesions did not display any flow. CONCLUSION: In pediatric patients, Doppler US is a noninvasive, easily available, and rapid mode of investigation of vascular lesions and can help confirm the diagnosis of VM when it shows a characteristic flow pattern.


Subject(s)
Arteriovenous Malformations/diagnostic imaging , Ultrasonography, Doppler , Adolescent , Adult , Blood Flow Velocity/physiology , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Veins/abnormalities , Veins/diagnostic imaging
7.
J Am Acad Dermatol ; 34(6): 979-84, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8647991

ABSTRACT

BACKGROUND: Four years ago, we began seeing young children with an unusual, predominantly unilateral, morbilliform and eczematous, self-limited cutaneous eruption. It appeared to correspond to unilateral laterothoracic exanthem (ULE) reported from France and to an eruption described as "a new papular erythema of childhood" in the United States. OBJECTIVE: We conducted a prospective study of ULE to define its clinical evolution, pathology, and therapy. In addition, we performed epidemiologic and microbiologic investigations in an attempt to determine the cause of ULE. METHOD: We studied 48 children with ULE. In some patients, blood, urine, stool, as well as skin biopsy specimens were analyzed. RESULTS: ULE is a morbilliform, eczematous eruption that often begins close to the axilla and spreads to become bilateral, although it usually retains a unilateral predominance. Patients' mean age at onset is 24.3 months, with a female predominance (2:1) and mean duration of 5 weeks, followed by spontaneous resolution that may or may not be improved with topical corticosteroids. It is characterized by a unique eccrine lymphocytic infiltration. Although signs of infection were reported by most patients, no one infectious agent was identified. No significant epidemiologic factor was found. CONCLUSION: ULE, in young children, is a self-limited morbilliform and scarlatiniform eruption that may represent a specific skin reaction to one or more infectious agents.


Subject(s)
Exanthema/pathology , Administration, Topical , Anti-Inflammatory Agents/therapeutic use , Axilla , Biopsy , Child, Preschool , Dermatologic Agents/therapeutic use , Eccrine Glands/pathology , Eczema/drug therapy , Eczema/microbiology , Eczema/pathology , Erythema/drug therapy , Erythema/microbiology , Erythema/pathology , Exanthema/drug therapy , Exanthema/physiopathology , Female , Glucocorticoids , Humans , Infant , Lymphocytes/pathology , Male , Prospective Studies , Quebec , Remission, Spontaneous , Sex Factors , Skin/pathology , Thorax
8.
J Am Acad Dermatol ; 28(5 Pt 2): 820-6, 1993 May.
Article in English | MEDLINE | ID: mdl-8491872

ABSTRACT

Three new unrelated cases of PIBIDS (Photosensitivity, Ichthyosis, Brittle, sulfur-deficient hair [trichothiodystrophy], Impaired intelligence, Decreased fertility, and Short stature) are reported. Decreased survival of skin fibroblast lines after UVB exposure was found. All three male patients had hypogonadism and primary end-organ gonadal failure. Striking osteosclerosis was present in all three patients. To the best of our knowledge the third patient is the first reported case of a black man with PIBIDS.


Subject(s)
Hair/abnormalities , Hypogonadism , Osteosclerosis , Photosensitivity Disorders , Sulfur/deficiency , Adult , Age Determination by Skeleton , Body Height , Child, Preschool , Face , Humans , Hypogonadism/pathology , Ichthyosis/pathology , Intellectual Disability , Male , Osteosclerosis/pathology , Photosensitivity Disorders/pathology , Sexual Maturation , Syndrome
9.
Pediatr Dermatol ; 8(3): 189-93, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1745626

ABSTRACT

Four children under 2 years of age were treated at our hospital in the last three years with a recurrent vesiculopustular eruption of the scalp, variably extending to the face and limbs. All cases followed a cyclical pattern. Three of the children had a moderate response to topical steroids, and one went into remission after a two-month course of erythromycin. Ethnic origin may be an important predisposing factor. Histologically, all patients showed a moderate mixed inflammatory infiltrate with numerous eosinophils centered around hair follicles. Peripheral white blood cell count showing leukocytosis with eosinophilia was observed in those cases measured, but no consistent immunologic abnormalities could be identified.


Subject(s)
Eosinophilia , Folliculitis , Eosinophilia/diagnosis , Eosinophilia/drug therapy , Folliculitis/diagnosis , Folliculitis/drug therapy , Humans , Infant , Infant, Newborn , Male , Steroids/therapeutic use
10.
J Am Acad Dermatol ; 22(1): 94-100, 1990 Jan.
Article in English | MEDLINE | ID: mdl-2298969

ABSTRACT

In a double-blind, vehicle-controlled study, all of six psoriatic plaques treated with intralesional cyclosporine administered three times weekly for 4 weeks showed complete clearing or incomplete but significant clearing in comparison with vehicle-treated plaques (p less than 0.01). Epidermal thickness decreased from 0.42 +/- 0.07 to 0.27 +/- 0.08 mm at 4 weeks (p less than 0.03). Biopsy specimens obtained on day 5, before any clinical improvement, revealed a significant reduction of epidermal DR+CD1- antigen-presenting cells, epidermal and dermal monocytes, and keratinocyte intercellular adhesion molecule-1 expression. By day 5 the stratum corneum reverted to normal in the plaques receiving cyclosporine. Pain at the injection site was the major side effect. Steady-state blood cyclosporine levels ranged from 20 to 30 ng/ml during the first 12 hours after injection and became undetectable at 48 hours. These data suggest that cyclosporine improves the skin of patients with psoriasis by a local mechanism of action.


Subject(s)
Cyclosporins/therapeutic use , Psoriasis/drug therapy , Adult , Antigen-Presenting Cells/pathology , Cell Adhesion Molecules/analysis , Cyclosporins/administration & dosage , Cyclosporins/blood , Double-Blind Method , Epidermis/pathology , Humans , Injections, Intralesional , Langerhans Cells/pathology , Pharmaceutical Vehicles , Placebos , Psoriasis/immunology , Psoriasis/pathology , Random Allocation , T-Lymphocytes/pathology , Time Factors
11.
J Am Acad Dermatol ; 21(6): 1235-40, 1989 Dec.
Article in English | MEDLINE | ID: mdl-2584461

ABSTRACT

5-Bromodeoxyuridine (BUDR), a halopyrimidine thymidine analogue, is incorporated into the DNA of dividing cells and causes photoradiosensitization. Twenty-five patients with malignant astrocytomas were treated with continuous intracarotid BUDR radiosensitization and radiotherapy for 8 1/2 weeks. Unique dose-limiting mucocutaneous complications were encountered. Ipsilateral facial dermatitis with epilation of eyebrows and eyelashes, ocular irritation, and bilateral nail dystrophy developed in all patients. Less common reactions included oral ulceration in six patients, body exanthem on the trunk in five, and atypical erythema multiforme major in one.


Subject(s)
Astrocytoma/therapy , Brain Neoplasms/therapy , Bromodeoxyuridine/adverse effects , Radiation-Sensitizing Agents/adverse effects , Radiodermatitis/etiology , Alopecia/etiology , Astrocytoma/diagnostic imaging , Astrocytoma/drug therapy , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/drug therapy , Bromodeoxyuridine/administration & dosage , Combined Modality Therapy , Conjunctivitis, Bacterial/etiology , Facial Dermatoses/etiology , Humans , Infusions, Intra-Arterial , Mouth Diseases/etiology , Nail Diseases/etiology , Radiation Dosage , Radiodermatitis/therapy , Radiography , Ulcer/etiology
12.
Arch Dermatol ; 125(7): 944-9, 1989 Jul.
Article in English | MEDLINE | ID: mdl-2662910

ABSTRACT

Epidermolysis bullosa acquisita (EBA), rarely reported in childhood, is described in a 10-year-old black girl. The age of onset during infancy and the clinical appearance mimicked hereditary dystrophic epidermolysis bullosa. Epidermolysis bullosa acquisita was diagnosed by direct immunofluorescence of perilesional skin, indirect immunofluorescence on normal epithelium and saline-split skin, direct immunoelectron microscopy, and immunoblotting of the patient's serum sample against partially purified EBA antigen/carboxyl domain of type VII collagen. Differentiation of mechanobullous disease in children is critical in that significant clinical benefit may be achieved in EBA with prednisone and/or dapsone therapy. A search for associated immunologic abnormalities and HLA-DR typing may help our understanding of EBA.


Subject(s)
Epidermolysis Bullosa/pathology , Age Factors , Biopsy , Child , Dapsone/therapeutic use , Diagnosis, Differential , Drug Therapy, Combination , Epidermolysis Bullosa/drug therapy , Epidermolysis Bullosa/genetics , Female , Fluorescent Antibody Technique , Humans , Immunoglobulin G/immunology , Prednisone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...